MRDD Archive

  • It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less [...]

    Do we need those nM-inhibitors?

    It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less [...]

    Continue Reading...

  • Prediction of toxic properties of small drug like molecules is a big challenge both from theoretical and practical points of view. Quantitatively people use different measures of toxicity such as [...]

    LD50 vs. MRDD: what’s death for a mice is good enough for a man

    Prediction of toxic properties of small drug like molecules is a big challenge both from theoretical and practical points of view. Quantitatively people use different measures of toxicity such as [...]

    Continue Reading...

  • Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before [...]

    Drug likeness: what do bioavailability and toxicity properties tell us about druglikeness?

    Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before [...]

    Continue Reading...

Get Adobe Flash playerPlugin by wpburn.com wordpress themes